LRRK2-targeting antisense oligonucleotide in Parkinson's disease: a phase 1 randomized controlled trial.
Mabrouk OS, Tichler B, Arnold HM, Thoma EC, Alexanian SM, Chen J, Liu TY, Hirschhorn B, Llorens Arenas R, Annand JW, Kapadnis U, Shomo AA, Glajch KE, Ferber K, Moroishi Y, Czerkowicz J, Inra J, Postuma RB, Gurevich T, Mir P, Morris HR, Aldred J, Brodsky MA, Ellenbogen A, Larson D, Tolleson CM, Siderowf A, Tzoulis C, Balaguer E, Marti MJ, Zhao HT, Kordasiewicz HB, Lane R, Hirst WD, Fradette S, Graham DL.
Mabrouk OS, et al. Among authors: tzoulis c.
Nat Med. 2026 Mar 24. doi: 10.1038/s41591-026-04262-4. Online ahead of print.
Nat Med. 2026.
PMID: 41876647